BIOSTAR PHARM-B (02563) has announced that its application to the Listing Committee of The Stock Exchange of Hong Kong Limited for the listing of and permission to deal in 148 million H shares, converted from an equivalent number of non-listed shares, has been approved. The board of directors is pleased to announce that the approval was granted on March 20, 2026.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments